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Summary: Copoly (L-lactic acid/~-valerolactone) microspheres (PLV-MS) contain-
ing p-hydroxybenzoic acid ester (ethyl (PE), r~-propyl (PP), n~-butyl (PB)) or 3',5'-
dibutyryl-2 '-deoxy-5fluorouridine (C4-FUdR) were prepared. The effect of temper-
ature on the drug release rate constant (KH) and the release mechanism from 
PLV-MS were investigated iT~ viti･o. All KH values observed for PLV-MS increased 
with a rise in temperature. In the relationship between log KH and the reciprocal 
of absolute temperature, relatively hydrophilic PE and PP gave the liner profiles 
throughout the temperature range examined; Iipophilic PB and C4-FUdR exhibit-
ed a break point at a temperature near glass transition temperature (Tg) of 
copolymer in the profiles. The relationship between the initial content of the drugs 
in the PLV-MS and KH suggested that PB was contained mainly in the suspended 
state in PLV-MS and that the release of PB from PLV-MS occurs by the dissolution 
and diffusion of PB in the copolymer phase, which formed PLV-MS. On the other 
hand, KH observed in PLV-MS containing PE or PP and the diffusion coefflcient of 
PE or PP in the PLV-MS were independent on the initial content of drugs. 
Therefore we estimated that PE or PP was contained in the completely dissolved 
state in PLV-MS. These results suggest that temperature dependency of the 
release rate from PLV-MS is governed by the states of contained drug' in PLV-MS. 
Keywords: copoly (L-lactic acid/6-valerolactone); microsphere; release mechanism; 
tem perature 
Introduction 
Various approaches to developing fine particles (for example, microspheres and nanos-
pheres) as the drug carrier have been studied. Once these carriers are delivered to the 
target site in the body, the drug should be released at an appropriate rate from the carri-
er. We reported previously on the release behavior of a lipophilic prodrug, 5-fluoro-2'-
deoxyuridine (3 ',5 '-diacyl5-fluor0-2 '-deoxyuridine), from poly (L-lactic acid) microspheres 
(PLA-MS) in; vitro.i'2} The prodrug release from the PLA-MS was enhanced in the pres-
ence of an esterase, an enzyme catalyzing the hydrolysis of the prodrug to hydrophilic 5-
fluoro-2'deoxyuridine (FUdR). Albumin, which increased the apparent solubility of the 
prodrug itself in the release medium, also accelerated the release rate. These results 
indicated that the drug release proceeded mainly by diffusion of the drug in the aqueous 
medium, which had penetrated into the capillaries or cracks formed within PLA-MS 
because of a crystalline nature of PLA. This characteristic of the drug release from PLA-
MS suggested that the prediction of the drug release rate il~ vivo from in vitro may be 
difficult. When microspheres are prepared by using a polymer that is in a rubbery state 
at body temperature, the drug release would be controlled by the diffusion of the drug in 
the polymer matrix itself, not in the aqueous channels or cracks. Therefore, these 
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microspheres could be useful to obtain information about the difference in the drug 
release property between ir~ vitro and i72; vivo. Copoly (Llactic acid/6-valerolactone) 
(PLV), an average molecular weight (Mw) of which is about 10,000, has glass transition 
temperature (Tg) near body temperature.3) Such a copolymer is in a glassy state at tem-
peratures below Tg and in a rubbery state at temperatures above Tg. By the use of PLV 
having Tg below body temperature to prepare PLV microspheres (PLV-MS), it may be 
possible that the drug release from PLV-MS is suppressed by a glassy state of PLV at low 
temperature during storage, and the drug release is forwarded by the change of PLV 
phase after administration of PLV-MS in vivo. By the use of PLV having Tg above body 
temperature, a thermosensitive polymer carrier (on-off drug release system) applicable, 
for example, to hyperthermic treatment in cancer therapy may be designed. Although 
many thermosensitive carriers such as hydrogel and liposomes, have been investigat-
ed,4-8) reports concerning an approach by microspheres employing biodegradable polymer 
are limited.9,*o) 
In the present study, p-hydroxybenzoic acid ethyl ester (PE), phydroxybenzoic acid r~-
propyl ester (PP), p-hydroxybenzoic acid n-butyl ester (PB), and 3 ',5'dibutyryl-FUdR 
(C4-FUdR) were used as model drugs to prepare PLV-MS. PE, PP, and PB were used to 
examine relationship between the physicochemical property and the drug release, and 
C4-FUdR was used as a model antitumor drug. The effect of temperature on the drug 
release rate from PLV-MS, the relationship between the drug release rate and Tg, and 
the mechanism of the drug release have been investigated. 
Ex perimental 
Material s 
PLV (L-lactic acid/6-valerolactone, 90/10, mol%, Mw = 11,500, Tg = 25'C, all data given 
by the supplier) was purchased from Taki Chemical Co. (Hyogo, Japan). PE, PP, and PB 
were purchased from Tokyo Kasei Kogyo Co. (Tokyo). FUdR was a gift from Yamasa 
Shoyu Co. (Chiba Pref., Japan). C4-FUdR was synthesized by the procedure described by 
Nishizawa et al.n) The compound was identified by elemental analysis, nuclear magnetic 
resonance (NMR), and mass spectrum (MS). The compound was more than 98% pure, as 
shown by one major peak by high-performance liquid chromatography (HPLO. Porcine 
liver esterase suspension was purchased from Sigma Chemical Co. (St. Louis, Mo., 
U.S.A.). The esterase suspension (2,600 units/mD in 3.2 M (NH4)2SO* solution was diluted 
with 0.01 M phosphate buffer (pH 7.4) to give a final concentration of 100 units/ml; the 
resultant solution was then filtered through a membrane filter (0.45 um), Toyo Roshi 
Co., Ltd., (Tokyo). The esterase preparation was stored at 4'C until use. All other chemi-
cals were commercial reagent grade products. 
Measurement ofpartitiorb coe/~cien;ts 
The apparent partition coefflcients of the drugs were determined in a methylene chlo-
ride/water system. A weighed amount of each drug was dissolved in methylene chloride 
(4 mD. Water (4 mD was added to the organic solution, which was shaken for 10 min. 
The mixture was permitted to stand for 48 h at 4'C. Then the drug concentration in the 
aqueous layer was determined by HPLC. 
Preparation Of PLV-MS 
PLV-MS containing PE, PP, and PB were prepared by the solvent-evaporation method 
similar to that reported previously.2) The weighed amount of each drug (5-20 mg) and 
PLV (lOO mg) was dissolved in methylene chloride (2 mD. The organic solution was then 
dispersed in 1.5% polyvinyl alcohol solution (90 mD under stirring at 500 rpm by means 
of a three-bladed propeller. The stirring was continued for 3 h at 4'C. In the case of PLV-
MS containing C4-FUdR, C4-FUdR (10 mg) and PLV (lOO mg) were dissolved in methyl-
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ene chloride (4 ml). The organic solution was then dispersed in 1.5% polyvinyl alcohol 
solution (90 ml) under vigorous stirring with ultra sonicator (150 W) in a cooling bath. 
The stirring was continued for 3 min to make an o/w emulsion, and the emulsion was 
then stirred at 2.000 rpm with homogenizer for 6 h at 4'C. The hardened PLV-MS were 
washed with water and freezedried. 
Determination of sizes Of PLV-MS 
The median diameters of PLV-MS were measured by a particle analyzer (SALD-1100, 
Shimadzu, Kyoto, Japan). 
Determil~atior~ of drug corttents ir~ PLV-MS 
In the case of PLV-MS containing PE, PP, and PB, a weighed amount of PLV-MS con-
taining each drug was dissolved in chloroform, and the drug concentration was deter-
mined spectrophotometrically at 265 nm. In the case of PLVMS containing C4-FUdR, a 
weighed amount of PLV-MS was dissolved in acetone, and the solution was diluted with 
acetonitrile. The drug concentration of the solution was determined by HPLC. The drug 
contents of PLVMS (weight ratio, drug/PLV-MS, %) were then calculated. 
Effect of temperature on d/'ug release /'ate fl'om PLV-MS i/1~ vitro 
To study the effect of temperature on the drug release rate from PLV-MS ir~ vitro, 
release studies were carried out at various temperatures (17-42'O by the following 
method. The weighed amount of PLV-MS in a flask was suspended in water. The flask 
was immersed in a shaker bath maintained at indicated temperature and shaken hori-
zontally. At fixed time intervals, an aliquot of the solution was withdrawn, and an appro-
priate volume of fresh medium was added to the release medium to maintain a sink con-
dition, in which the concentration of each drug in the medium was less than 50/0 of its 
solubility. The amount of drug released was calculated after HPLC determination of the 
solution. 
The apparent release rate constants (KH) were obtained by the method described by Y. 
Aso et al.$) Linear Higuchi plots (percent of drug released versus square root of time) for 
the data were made, and KH were then calculated from the slope of the straight lines. 
Effect ofpH and estel'ase on drug 7'elease from PLV-MS ir2; vitro 
To study the effect of pH and esterase on drug release from PLV-MS containing PB irb 
vit/'o, release studies were carried out at 37'C in the sameway as those described above. 
Water, O.OI M phosphate buffer solution (pH 7.4), 0.02 M disodium hydrogen phosphate 
solution (pH 8.5), and O.OI M phosphate buffer (pH 7.4) containing 2.3 unit/ml porcine 
liver esterase were uscd as a release medium. 
HPLC assay 
The HPLC system (LC-3A, Shimadzu) equipped with a variable wavelength detector 
(SPD-2A, Shimadzu) was used. The stationary phase was LiChrospher RE-18e (of um) 
packed in a stainless steel column (4.0 X 250 mm, Merck). The mobile phases were water 
: acetonitrile (60 : 40) for PE, (50 : 50) for PP, (40 : 60) for PB, and 0.19(:o acetic acid solu-
tion : acetonitrile (40 : 60) for C4-FUdR, with a flow rate of 1.0 ml/min. The wavelengths 
were 253 nm for PE, PP, and PB and 270 nm for C4-FUdR. 
Re~sults and Discussion 
Preparation Of PLV-MS 
PE, PP, and PB were used as model drugs to prepare PLV-MS (Table I). The drug con-
tents in PLV-MS containing PE, PP, or PB increased when the initial loading amount of 
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TABLE I. Apparent Partition Coefficients of Drugs, Amounts of Drug and PLV Used for Preparation of 
MS, Drug Contents in MS, and Median Diameter of MS 
Drug 
PE 
PE 
PE 
PP 
PP 
PP 
PB 
PB 
PB 
C4-FUdR 
log P 
1.33 
1.86 
2.45 
2.55 
Amount for preparation 
Drug 
(mg) ?
14 
20 ?
14 
20 ?
14 
20 
10 
PLV 
(mg) 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
Drug content"} Median diameter) 
in PLV-MS (%) (um) 0.57 ~ 0.02 
1,15 ~ 0.10 
1,71 ~ 0.11 
1.30 ~ 0.11 
2.59 ~ 0.20 
3.71 d:: 0.30 
1,65 ~ 0.36 
4.02 ~ 0.77 
7.29 ~ 0.79 
2.04*) 
53.16 ~ 3.47 
52.40 ~ 2.63 
55.89 ~ 5.17 
54.14 ~ 3.74 
49.14 ~ 3.12 
48.57 ~ 1.94 
55.34 ~ 3.17 
49.46 ~ 3.96 
50.46 ~ 2.60 
2.83*) 
a) Mean~S.D.; n = 3. b)n)=1. 
each drug was increased. When the same amount of each drug was used, the drug con-
tents increased as the lipophilicity of the drug increased. Partitioning of the drug 
between the organic phase and aqueous phase during the solvent-evaporation process 
would greatly affect the final content of the drug in the PLV-MS. Therefore the highly 
lipophilic drugs were retained in the polymer phase. In preliminary experiments, the 
incorporation efficiency of FUdR in PLV-MS was very low (1.6%) because FUdR was a 
hydrophilic drug. On the other hand, the incorporation efficiency of C4-FUdR in PLV-MS 
was 22.4%. Therefore the chemical modification of FUdR is helpful to improve the effi-
ciency of drug incorporation into PLVMS in the solventevaporation method. 
The diameter of PLV-MS containing C4-FUdR was 2.83 um (median diameter). When 
compared with larger microspheres, these small microspheres may be practically advan-
tageous in applying to various routes of administration. However, since particle size con-
trol was difficult in the preparation process. PLV-MS containing PE, PP, or PB were pre 
pared without ultrasonication, and the median diameter of PLV-MS was about 50 um. 
The diameters of PLVMS prepared by the simplified method were independent on drug 
species (i.e., PE, PP, or PB) and drug contents. 
Although the contained drug may affect the Tg values of polymers, we could not detect 
the Tg values of PLV-MS on DSC analysis. 
Effect of temperature on) drug release rate from PLV-MS 
To study the effect of temperature on drug release from PLVMS (shown in Table D in 
vitro, the release studies were ca"*'ried out at indicated temperatures (42, 37, 32, 27, 22, 
17'O around Tg for 6 h. Since the shape and particle size of PLV-MS were not changed 
after the release studies and the release profiles showed no abrupt change, the degrada-
tion or agglomeration of PLV-MS could be negligible during the release study. To com-
pare the drug release rate from each PLVMS, the apparent release rate constants (KEl) 
at the initial release were obtained from Linear Higuchi plots, according to the method 
described by Y. Aso et al.9} Log KH ver8us the reciprocal of absolute temperature (1/T) 
were plotted in Fig. 1. A11 release rates from PLV-MS increased steeply with the rise in 
temperature. Relatively hydrophilic PE and PP gave the liner profiles throughout the 
temperature range examined, and the break point was observed in the profiles for rela-
tively lipophilic PB and C4-FUdR. Although the Tg values of PLV-MS were unknown, 
the break points were suggesting that these values could be similar to that of PLV with-
out drugs. Especially in the case of C4-FUdR, the release rate increased rapidly when 
the temperature rose to 27'C (above Tg of PLV) from 22'C (below Tg of PLV). Therefore if 
a PLV sample having Tg above body temperature, for example 40'C, is available as the 
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material for microspheres, it may be possible to develop an on-off drug release system 
because the drug release is initiated by the heating of a target site where the micros-
pheres were delivered. As a general rule of polymer, the movement of polymer chains 
rapidly increases with the rise in temperature, and at a temperature above Tg, the per-
meability of gas molecules suddenly increases with a polymer drop in viscosity. It is also 
known that temperature dependence of the drug" transport in the polymer is variously 
changed not only by the size of drug molecule, which is related to the diffusional resist-
ance, but also by the difference in mechanism of the drug transport in each polymer 
phase at temperatures above and below Tg. We also think that the mechanism of the 
drug release from PLV-MS was changed by the change in the polymer phase at a temper-
ature across Tg; however, the break point was not always observed in the profiles (Fig. 
1). The existence of a break point may depend on the physicochemical properties of each 
drug. 
The mechanism of drug release f7'om PLV-MS at a temperature above Tg 
The attempt to clarify the mechanism of drug release from PLV-MS is very important 
not only on the design of PLV-MS, but also on the understanding of the dif:ference of tem-
perature dependency between the drugs. 
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Effect of Temperature on the Apparent Release Rate Constant (KH:) of PLV-MS 
A: KH of PLV-MS containing PE, B: KH of PLV-MS containing PP, C: KH: of PLV-MS 
containing PB, D: KH of PLV-MS containing C4-FUdR. A, PE content; l, 0.570/0; 
A, 1.15a/c; O, 1.17c~/0; B, PP content; [], 1.30~/0; A, 2.50O/o; O, 2.59%; C, PB content; 
i], 1.65a/o; A, 4.02%; O, 7.29a/o; D, C4-FUdR content; B, 20.4% (Median diameter = 
2.83 um). The data are expressed as the mean ~ S.D. (n = 3). Interrupted lines 
show Tg of PLV. 
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The release rate of a drug from a homogeneous spherical matrix has been described by 
Higuchi *2) and Baker and Lonsdale.*3) When the contained drug is dissolved completely in 
the matrix and the drug release from the matrix occurs by diffusion in the matrix, the 
drug release from the matrix is defined by the following equation. 
F = 6(Dt/r'lc)*/' _ 3Dt/r' (F < 0.4) (1) where F and D are the ratio of the drug released at time t and the diffusion coefficient of 
the drug in the matrix, and r is the radius of the spherical matrix. On the other hand, if 
the contained drug is suspended in the matrix, which is in excess of its solubility in the 
matrix, and the drug release from the matrix occurs by the dissolution and subsequent 
diffusion of drug in the matrix, it is defined by, the following equation. 
(3/2) [1 (1 F)~*] - F = (3DCms/r Co)t (2) where Cms and Co are the solubility of the drug in the matrix and the concentration of 
the drug in the matrix at t = O, respectively. A comparison of the drug release profiles 
from PLV-MS with various Co values can be a convenient method to judge the release 
mechanism. If the mechanism of the drug release from PLV-MS follows eq. 1, the drug 
release rate (change of F with t) is independent of the initial drug contents in PLV-MS. If 
it follows eq. 2, the drug release rate from PLV-MS decreases as the initial drug content 
in PLV-MS is increased because Co is in the denominator of the right side (eq. 2). 
On the basis of these theories, KH values at 42'C above Tg of PLV-MS containing PE, 
PP, or PB (the median diameter of each PLV-MS is approximately 50 um) are plotted 
against the drug content of each PLV-MS (Fig. 2). Only in the case of PLV-MS containing 
PB, the greater the drug contents in PLV-MS, the smaller the value of KH became. From 
this result, we assumed that the mechanism of the release from PLV-MS containing PB 
is described by eq. 2 rather than by eq. 1. If the assumption is true, the plot of the left 
side of eq. 2 versus t should be a straight line because 3DCms/r'Co is constant in the 
right side of eq. 2. Therefore the values of the left side of eq. 2 (i.e. , 3/2 [1 - (1 - F)~*] _ F) 
were calculated from data of the cumulative amount of PB released from PLVMS in 
release studies at 42'C. The values are then plotted versus time (Fig. 3). A straight line 
was found in each drug content of PLV-MS. Each slope (KB) then substituted for 
3DCms/r'Co was plotted versus the reciprocal of the drug content (Fig. 4). Figure 4 
shows a linear relationship as indicated by eq. 2. These results suggested that PB was 
contained mostly in a suspended state in PLV-MS and released from PLV-MS by the dis-
solution and subsequent diffusion of PB in the homogeneous copolymer phase that 
formed PLV-MS, and it seemed reasonable for the release of PB from PLVMS to be 
expressed by eq. 2. On the other hand, since there was no clear tendency that the release 
rate of PE or PP from PLV-MS was dependent on the drug contents in PLV-MS, we esti-
mated that PE and PP were completely dissolved in PLV-MS. Because we think PE or 
PP is completely dissolved in PLV-MS and the release from PLV-MS occurs by diffusion 
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B PE A PP; O, PB. The data are expressed as the mean ~ S.D. (r~ = 3). 
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of the drug in the homogeneous copolymer phase that forms PLV-MS, it is reasonable to 
assume that eq. I is applicable to describe the release of PE and PP from PLV-MS. 
Therefore eq. 3 was obtained by differentiating eq. 1, and the diffusion coefflcient (D) 
was then obtained by eq. 3. , dF/dt = 3(D/r27ct)*/2 _ 3D// (3) The release rate (dF/dt) obtained by release studies was plotted vel'sus 1/t*/2, and the 
slopes were then calculated from the plot. Since the slope equals 3(D//'27c)*/2, the diffusion 
coefficient (D) was calculated, where (the median diameter/2) of PLV-MS was substituted 
?
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Effect of Esterase and pH Condition on 
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taining PB at 37'C 
l, distill d water; <>, 0.01 M phosphate 
buffer (pH 7.4); A, buffer containg 2.3 
untits/ml esterase; O, 0.02 M disodium 
hydrogenphosphate solution (pH 8.5). 
The data are expressed as the mean ~ 
S.D. (r2; = 3). In the case of buffer con-
taining esterase, the percentages of 
release were calculated from the total 
amount of drug released (PB plus p-
hydroxybenzoic acid). 
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by r. The relationship between the obtained D and the drug contents in PLVMS is 
shown in Fig. 5. The values of D were approximately constant irrespective of the drug 
and drug content. From these results it can be estimated that the mechanism of drug 
release from PLV-MS becomes different in the different states of dissolved drug in PLV-
MS, and the state of dissolved drug in PLV-MS is dependent on the lipophilicity of the 
drugs. To study the effect of PLV on the melting point of each drug, the depression of the 
melting point was measured by a differential scanning calorimeter. The depression of 
the melting point of PE and PP was 20.3"C and 11.6'C, respectively, and that of PB was 
only 2.6'C. This also supports our consideration described above. Figure I shows that 
the release rates of PB from PLV-MS slightly increase with temperature in the tempera-
ture range above Tg of PLV. This may be explained that the releases of PB increase by 
the gentle increase in drug solubility in PLV-MS at a higher temperature. On the other 
hand, the release rates of PE and PP increase with an increase in D, which was favored 
by decreased viscosity at a higher temperature. C4-FUdR may be suspended in PLV-MS 
like PB because the lipophilicity of C4-FUdR is nearly equal to that of PB, and the pro-
file of C4-FUdR in Fig. I was similar to that of PB. 
We reported previously that the drug release from PLAMS is largely influenced by 
albumin and esterase in release medium because the drug release from PLA-MS would 
be driven by dissolution and diffusion of the drug in an aqueous medium that had pene-
trated through drugpresented capillaries or cracks formed within PLA-MS.1,') On the 
other hand, considering the case of the drug release from PLV-MS at a temperature 
above Tg, since we thought that the diffusion of the drug in the copolymer phase forming 
PLV-MS is a ratedetermining step, we expected that the drug release from PLV-MS is 
not influenced appreciably by various body fluid components. Therefore to clarify the 
effect of pH and esterase on the drug release from PLV-MS, the release studies from 
PLV-MS containing PB were carried out (Fig. 6). On the addition of the esterase, PB was 
converted to p-hydroxybenzoic acid; the percent of release at an indicated time was cal 
culated by the total amount of the drug released, that is, PB plus phydroxybenzoic acid. 
The results differed from the case of PLAMS. It was shown that the drug release from 
PLV-MS was affected neither by high pH condition, which increases the solubility of the 
drug in the release medium, nor by esterase, an enzyme catalyzing the hydrolysis of PB 
to hydrophilic p-hydroxybenzoic acid. This result also supports our opinion that the dif-
fusion of the drug in the copolymer phase that formed PLVMS is a rate-determining 
step in the drug release process for PLV-MS. 
In conclusion, the microspheres were prepared by use of PLV (Tg = 25'O, which is in a 
rubbery state at body temperature. The drug release rates from PLV-MS were increased 
with a rise in temperature. Especially in the case of C4-FUdR, the release rate increased 
steeply when temperature exceeded Tg of PLV. Therefore if PLV having an optimum Tg 
can be used as the material of the microspheres, it is possible to develop an onoff release 
system. On the other hand, since it was suggested that the drug release from PLV-MS at 
a temperature above Tg is controlled by the diffusion of the drug in the copolymer phase 
that formed PLV-MS, it is expected that a comparable drug release rate can be obtained 
both in; vitro and in vivo until the biodegradation of PLV becomes remarkable. 
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